Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD, Sandborn WJ, Feagan BG.

Aliment Pharmacol Ther. 2013 Sep;38(5):447-59. doi: 10.1111/apt.12407. Epub 2013 Jul 14. Review.

2.

Drug monitoring of biologics in inflammatory bowel disease.

Eser A, Primas C, Reinisch W.

Curr Opin Gastroenterol. 2013 Jul;29(4):391-6. doi: 10.1097/MOG.0b013e328361f7f6. Review.

PMID:
23703367
3.

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.

Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH.

Aliment Pharmacol Ther. 2013 Jun;37(12):1172-83. doi: 10.1111/apt.12330. Epub 2013 May 7.

4.

Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.

Lee LY, Sanderson JD, Irving PM.

Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1078-85. doi: 10.1097/MEG.0b013e32835558cf.

PMID:
22647738
5.

Anti-TNF therapy in inflammatory bowel diseases: a huge review.

Peyrin-Biroulet L.

Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43. Review.

PMID:
20485259
6.

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.

Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C.

Inflamm Bowel Dis. 2014 Oct;20(10):1714-21. doi: 10.1097/MIB.0000000000000138.

PMID:
25069030
7.

Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.

Felice C, Marzo M, Pugliese D, Papa A, Rapaccini GL, Guidi L, Armuzzi A.

Expert Opin Biol Ther. 2015;15(8):1107-17. doi: 10.1517/14712598.2015.1044434. Epub 2015 May 7. Review.

PMID:
25947043
8.

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.

Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T.

World J Gastroenterol. 2014 May 7;20(17):5031-5. doi: 10.3748/wjg.v20.i17.5031.

9.

Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.

van Schaik T, Maljaars JP, Roopram RK, Verwey MH, Ipenburg N, Hardwick JC, Veenendaal RA, van der Meulen-de Jong AE.

Inflamm Bowel Dis. 2014 Dec;20(12):2292-8. doi: 10.1097/MIB.0000000000000208.

PMID:
25230167
10.

Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Rutgeerts P, Van Assche G, Vermeire S.

Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63. Review.

11.

Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.

Am J Gastroenterol. 2014 Jul;109(7):1055-64. doi: 10.1038/ajg.2014.106. Epub 2014 May 6.

PMID:
24796769
12.

The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.

Sandhu A, Alameel T, Dale CH, Levstik M, Chande N.

Aliment Pharmacol Ther. 2012 Jul;36(2):159-65. doi: 10.1111/j.1365-2036.2012.05141.x. Epub 2012 May 23.

13.

The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.

Mitchell RA, Shuster C, Shahidi N, Galorport C, DeMarco ML, Rosenfeld G, Enns RA, Bressler B.

Can J Gastroenterol Hepatol. 2016;2016:5203898. Epub 2016 Nov 10.

14.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.

Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2. Review. Erratum in: Am J Gastroenterol. 2011 Feb;106(2):375. Watermayer, G [corrected to Watermeyer, G].

PMID:
21045814
15.

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.

Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J.

Gut. 2010 Oct;59(10):1363-8. doi: 10.1136/gut.2010.212712. Epub 2010 Jun 29.

PMID:
20587545
16.

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.

Am J Gastroenterol. 2014 Aug;109(8):1250-6. doi: 10.1038/ajg.2014.146. Epub 2014 Jun 10.

PMID:
24913041
17.

The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease.

Joosse ME, Samsom JN, van der Woude CJ, Escher JC, van Gelder T.

Inflamm Bowel Dis. 2015 Sep;21(9):2214-21. doi: 10.1097/MIB.0000000000000420. Review.

PMID:
26284297
18.

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.

Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ.

Am J Gastroenterol. 2010 May;105(5):1133-9. doi: 10.1038/ajg.2010.9. Epub 2010 Feb 9.

PMID:
20145610
19.

Optimizing anti-TNF treatments in inflammatory bowel disease.

Ben-Horin S, Kopylov U, Chowers Y.

Autoimmun Rev. 2014 Jan;13(1):24-30. doi: 10.1016/j.autrev.2013.06.002. Epub 2013 Jun 19. Review.

PMID:
23792214
20.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

Supplemental Content

Support Center